Avacta Group (LON:AVCT) Shares Up 15.5% – Time to Buy?

Avacta Group Plc (LON:AVCTGet Free Report) shot up 15.5% on Thursday . The company traded as high as GBX 82.74 and last traded at GBX 82. 7,010,121 shares changed hands during mid-day trading, an increase of 257% from the average session volume of 1,962,845 shares. The stock had previously closed at GBX 71.

Avacta Group Price Performance

The company has a debt-to-equity ratio of 14,168.75, a current ratio of 0.79 and a quick ratio of 4.96. The company has a 50 day moving average price of GBX 69.72 and a 200 day moving average price of GBX 66.83. The firm has a market cap of £374.14 million, a PE ratio of -4.70 and a beta of 1.12.

Avacta Group Company Profile

(Get Free Report)

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISIONĀ® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

See Also

Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.